CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 target
Drug / intervention
Enbrel (Etanercept)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00135720
NCT00135720Phase 2Completed

A Double-Blinded, Placebo-Controlled Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

Massachusetts General Hospital·interventional·Posted Aug 26, 2005·Updated Jun 3, 2015

In Brief

A Phase 2 clinical trial evaluating Enbrel (Etanercept) for Pemphigus Vulgaris. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of the study is to find out about the effectiveness and the safety of an investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus vulgaris is a potentially life threatening blistering condition that currently has no cure. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Etanercept has been approved by the FDA to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriasis, but not pemphigus vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 26, 2005
Enrollment StartJun 1, 2004
Study CompletionNov 1, 2007
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Enbrel (Etanercept)drug